Thomas D. Duensing

Essen Instruments, Inc. engages in the development and manufacture of cell and bead based screening solutions. It offers phenotypic drug discovery, antibody discovery and in vitro toxicity testing. The firm’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology and life science research. The company’s products are used in biologics discovery, small molecules, in vitro tox and cellular research antibody applications. The company was founded by R. Terry Dunlay, Larry A. Sklar, and Bruce S. Edwards in 2006 and is headquartered in Ann Arbor, MI.

Cellomics, Inc. provides imaging technology products and services. It is a provider of technologies and products for the advancement of cell science research, including complete systems for high-content imaging of cells, tissues and whole organisms. The firm's platform includes automated imaging instruments, image analysis software, data management and bioinformatics software, coupled with reagents, cell-culture media, sera and specialty media formulations, along with laboratory automation and services. The company's offering is aimed at providing life science researchers with a quantitative, automated approach to understanding the biology of cells, including stem cells and cell systems, supporting all aspects of the drug discovery process as well as academic and systems biology research. Cellomics was founded on October 1996 and is headquartered in Pittsburgh, PA.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma